AGC Inc. (Tokyo; www.agc.com) has announced its decision to expand facilities at its pharmaceuticals CDMO (Contract Development & Manufacturing Organization) business subsidiary AGC Pharma Chemicals Europe S. L. U., headquartered in Catalonia, Spain.
This initiative will not only upgrade existing production facilities to achieve 1.3 times the capacity of the current production level, but also establish a brand-new R&D facility. The new R&D facility is scheduled to begin operation in March 2021, while the expanded facility is scheduled to begin in May 2022.
AGC Pharma Chemicals Europe, a synthetic pharmaceutical CDMO, was acquired from Boehringer Ingelheim in March 2019 in order to establish a synthetic pharmaceutical production capability in Europe, to supply active pharmaceutical ingredients and their intermediates. In October of the same year, the name was changed from Malgrat Pharma Chemicals to its current AGC Pharma Chemicals Europe. The company has a long history and wealth of experience in the manufacture of GMP-compliant pharmaceutical ingredients, and is capable of handling a wide range of production from development drugs to commercial drugs.
The synthetic pharmaceutical CDMO market is growing at over 7% annually, while the number of contracts handled by the company are growing at an even faster rate. To satisfy this accelerating demand, existing production facilities will be upgraded to increase pharmaceutical production capacity by 1.3 times that of the current level. A new micronization facility will also be introduced to respond to the increasing demand for micronization of active pharmaceutical ingredients. In addition, a brand-new R&D facility will be built which will enable development of processes from lab scale to commercial production, and to deliver better and faster services to customers.